MDS
Myelodysplastic syndromes (MDS) are diseases of the blood cells and bone marrow. MDS are a collection of myeloid malignancies characterized by one or more peripheral blood cytopenias. Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.
Advertisement
Advertisement
Dr. Colla describes her current research at MD Anderson, such as developing new therapeutic approaches to MDS.
The average rate of progression for CHIP to MDS or AML is about 1% per year, Dr. Patel explained.
A drug approval specific to CMML would catalyze a surge of interest in the hematology-oncology community.
The Leukemia and Lymphoma Society's CMML Initiative hopes for dedicated CMML trials and CMML-directed therapies.
A significant number of patients receiving ivosidenib had reduced levels of voriconazole and posaconazole.
The case study included four patients with CMML who had KRAS mutations and a multitude of autoimmune diseases.
The study also explored the role of this combination in transitioning patients to HSCT.
An FDA committee voted that the benefits of imetelstat outweigh the risks for the treatment of anemia in lower-risk MDS.
UM171 promotes degradation of the CoREST1 complex and reduces levels of chromatin-bound MYC.
The CHMP of the European Medicines Agency recommended approval of luspatercept for transfusion-dependent anemia due to MDS.
Dr. Patel and the hosts discuss the TRANSFORM-1 study, MANIFEST-2, AUGMENT-101, and more.
Gilead said that it "will not pursue further development of magrolimab in hematologic cancers."
Oral decitabine plus cedazuridine is a safe and effective alternative to intravenous decitabine.
This episode of The HemOnc Pulse features Dr. Shastri, a physician-scientist, who discusses latest news in MDS.
Sanjay Patel, MD, discusses a study on spatial mapping of human hematopoiesis using bone marrow tissue.
Complete response was achieved in 14 patients (22%) in the sabatolimab group, versus 11 patients (18%) in the placebo group.
The panel shares their outlook for the future of MDS research and treatment.
Dr. Tanaka outlines a biomarker study that observed reduced inflammation in patients with MDS treated with luspatercept.
The panel discussed a study that assessed quality of life and PROs in patients receiving luspatercept for MDS.
The panel discusses whether starting treatment with luspatercept sooner in patients with MDS is beneficial.
Dr. Shammo shares her reaction to a study that assessed mutational burden and impact on primary outcomes in COMMANDS.
Dr. Safah outlines the findings from the full analysis of the COMMANDS trial.
The panel discusses the evolution of MDS therapy.
Dr. Safah gave an overview of myelodysplastic syndromes.
Dr. Venugopal offers her thoughts on the investigational drug KER-050 in lower-risk myelodysplastic syndromes.
The panel discusses forward-looking thoughts for the treatment of low-risk myelodysplastic syndromes.
The panel talks about the use of transplant for patients with low-risk myelodysplastic syndromes.
The panel discusses other treatments undergoing research for MDS, including imetelstat and KER-050.
The panel shared their thoughts on real-world data of luspatercept presented at ASH 2023.
The panel addresses continued MDS research needs.
The panel discusses appropriate treatment selection based on patient mutation status and comorbidities.
The panel shares their thoughts on the full analysis of the COMMANDS study.
The panel discussed the current slate of treatment options for patients with low-risk MDS.
Dr. Schienberg discussed luspatercept in MDS, selinexor in AML, and the difficulty of randomizing trials.
The study compared somatic mutations and variant allele frequencies in paired peripheral blood and bone marrow samples.
Dr. Guillermo Garcia-Manero outlined the final data update on luspatercept in patients with MDS in the COMMANDS trial.
Investigators reviewed cladribine in combination with low dose cytarabine (LDAC) and venetoclax.
In this video interview, Dr. Swoboda talks MDS highlights from ASH 2023, including the COMMANDS and IMerge trial.
Targeted next-generation sequencing of the full UBA1 locus was used to profile diagnostic and treatment-naïve samples.
Patients in the COMMANDS study were randomly assigned to luspatercept or epoetin alfa.
Of the patients included in the study, 67.6% were not transfusion dependent before initiating luspatercept.
OS was still inversely proportional to the IPSS-M, but the molecular risk stratification had no additional prognostic power.
Data differentiated the mechanisms of action of luspatercept from epoetin alfa in patients with transfusion-dependent LR-MDS.
Baseline mutational burden impacted response to erythropoiesis-stimulating agents in naïve patients with lower-risk MDS.
Venetoclax plus azacitidine was well tolerated and achieved favorable response rates in higher-risk myelodysplastic syndrome.
Researchers studied patients with LR-MDS who had received an erythropoiesis-stimulating agent as frontline therapy.
Amer Zeidan, MBBS, MHS, reflects on the COMMANDS study that compared luspatercept with epoetin alfa in MDS.
Rami Komrokji, MD, discussed the impact of luspatercept on the genomic landscape in patients with lower-risk MDS.
The study determined the maximum tolerated dose of CPX-351, but further studies are needed to evaluate its activity.
The study evaluated mesenchymal cell molecular features and sought modifications that might affect MDS.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
